XBiotech

Activities: Research & Development Pharmaceutical

Trending Articles

  1. LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
  2. Fasenra for EGPA: addressing unmet needs Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
  3. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  4. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
  5. Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

Related Content

Manufacturing

XBiotech to begin constructing new R&D facility on its 48 acre campus

XBiotech Inc. has announced that it plans to expand it’s campus headquarters with the construction of a new, state-of-the-art research and development facility
Research & Development

XBiotech Fluvid therapy to treat influenza and COVID-19 infections

The latest research findings suggest the therapy, designed to be effective against all known strains of influenza in addition to the COVID-19 virus, could provide an effective therapy for treating complex infections from one or more of these viruses

XBiotech appoints Dirk Arnold to its Scientific Advisory Board

XBiotech hires Trey Benson as Commercial Head

To lead commercial development of the company’s portfolio of therapeutic antibodies
Manufacturing

XBiotech buys automated vial filling machine

To increase its fill finish capabilities
Research & Development

XBiotech begins development of an antibody therapy for MRSA

Product comes out of True Human antibody discovery programme for identifying and cloning pharmacologically relevant antibodies from human donors
Subscribe now